InTouch
January / February 2026

ISPE Announces New International Board of Directors
ISPE
2025–2026 International Board of Directors

ISPE elected a new 2025–2026 International Board of Directors, which is responsible for the governance and strategic direction of ISPE.

The election was run by an independent third party, which provided ISPE with the final audited results. Board members assumed their elected positions at the 2025 ISPE Annual Meeting & Expo, held in Charlotte, NC, US, and virtually from 26–29 October. The following pharmaceutical industry leaders have been elected to positions on the 2025–2026 ISPE International Board of Directors.

Executive Committee

Vivianne Arencibia
Vice President, Head of Quality Auditing and Risk Management
Lonza AG
Chair
Ylva Ek
Founder
Robur Life Science Advisory AB
Vice Chair
David Churchward
Head of Operations Quality Compliance and External Affairs
AstraZeneca
Treasurer
Georg Singewald
Global Head of Quality & Compliance
Roche / Genentech
Secretary
Jeffrey Biskup
Executive Chairman of the Board
CRB
Past Chair
Mike Martin
President and CEO
ISPE
Ex Officio Non-Voting Member

Elected to a Second Term

Liz Dooley
Global Lead, Site Engineering, Synthetics
Johnson & Johnson

New Directors

Jose Caraballo-Oramas
Founder and Principal
JCO Global Advisory LLC
Victor Cruz
Sr. VP of Corporate Engineering and Global Health, Safety and Environmental
Eli Lilly & Company - Corporate Engineering
Francesco Intoccia
SVP Global Engineering, EHS & Sustainability
GSK

Board Members Continuing a Term in 2025-2026

The following individuals will be continuing a two-year term in 2025-2026.

Norman Goldschmidt
President
Genesis AEC
James Grunwald
Senior Vice President US Business Development
Arcadis
Shanshan Liu
Global Process Science & Regulator Director
Fedegari
Vivien Santillan
Regional Director, Asia
Novatek International

About the Author

ISPE
Shape the Future of Pharma
ISPE delivers technical and operational solutions to support across the global pharmaceutical and biopharmaceutical industry in the manufacture of quality medicines for patients.